The use of the KL-6 antigen as a predictive marker for the development of pulmonary fibrosis following COVID-19 has also been proposed by Xue et al. The study showed statistically higher values of KL-6 in the serum of patients who developed PF. This evidence concerns the gene MUC1 and COVID-19.